U.S. Markets close in 3 hrs 2 mins
Stocks to Watch

Sempra outbids Buffett for Oncor, Fiat Chrysler soars, Nike gets downgraded

TrovaGene, Inc. (TROV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.84+0.01 (+1.24%)
As of 12:57PM EDT. Market open.
People also watch
BIOCIDRAVSTMSRNESGYP

TrovaGene, Inc.

11055 Flintkote Avenue
Suite B
San Diego, CA 92121
United States
858-952-7570
http://www.trovagene.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full Time Employees55

Key Executives

NameTitlePayExercisedAge
Mr. William J. Welch M.B.A.Chief Exec. Officer, Principal Financial Officer and Director435.49kN/A55
Dr. Mark Erlander Ph.D.Chief Scientific Officer608.4kN/A57
Dr. Karsten Schmidt Ph.D.Chief Technology OfficerN/AN/A55
Ms. Elizabeth Anderson CPAVP of Fin. and Admin.N/AN/AN/A
Mr. George Samuel J.D.VP & Gen. CounselN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the United States. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor circulating tumor DNA (ctDNA) using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, which provides cancer monitoring by tracking and quantifying levels of ctDNA from either urine or blood samples, as well as intends to offer clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung and colorectal cancers, as well as targeting clinically validated resistance mutations for gene rearrangements, including ALK, RET, and ROS. In addition, it offers laboratory developed tests for pharmaceutical companies and third party laboratories. The company has a license agreement with Nerviano Medical Sciences to develop and commercialize therapeutic candidate PCM-075. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Corporate Governance

TrovaGene, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.